<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04413539</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A00729-30</org_study_id>
    <nct_id>NCT04413539</nct_id>
  </id_info>
  <brief_title>Evaluation of Impact of Disease on Quality of Life, Education and Socio-professional Integration of Adults and Parents of Children Living With Sickle- Cell Disease in France</brief_title>
  <acronym>DREPAtient</acronym>
  <official_title>Evaluation of Impact of Disease on Quality of Life, Education and Socio-professional Integration of Adults and Parents of Children Living With Sickle- Cell Disease in France</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Argo Sante</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Filière de santé maladies rares MCGRE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fédération des malades drépanocytaires et thalassémiques SOS Globi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>bluebird bio</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Argo Sante</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sickle cell disease (SCD) is the most common genetic disease in France. Its consequences on&#xD;
      patient's life-course and quality of life need to be precisely identified among French&#xD;
      patients and their family to be able to improve patients care according to their specific&#xD;
      needs.&#xD;
&#xD;
      The aim of the study is to accurately describe the impact of SCD on quality of life of&#xD;
      patients living in France, or their family (for minor patients). The consequences of the&#xD;
      disease on professional life, education and material condition of patients or their parents&#xD;
      will be described by the patients themselves.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a retrospective study. Patients or parents of minor patients living in France and&#xD;
      suffering from SCD will be informed about the study and enrolled during their usual&#xD;
      follow-up, or by patients' associations. They will be asked to answer an anonymous survey&#xD;
      online relating to their whole life-course with SCD and exploring different aspects of the&#xD;
      consequences of the disease on their life. It contains 4 different sections:&#xD;
&#xD;
        1. socio-demographic questions to establish a respondent profile&#xD;
&#xD;
        2. health status of the respondent to establish the severity of the disease&#xD;
&#xD;
        3. education, professional life, material and economic situation&#xD;
&#xD;
        4. quality of life through MOS SF-36 questionnaire This is a one-shot survey, which will&#xD;
           take approximatively 20 to 30 minutes to answer by the respondent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2, 2020</start_date>
  <completion_date type="Actual">April 27, 2021</completion_date>
  <primary_completion_date type="Actual">April 27, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Describe the disease impact on quality of life through description of professional life, education and material condition of patients, or their parents (for minor patients), suffering from sickle-cell disease and living in France.</measure>
    <time_frame>Once at enrollment</time_frame>
    <description>Measure of mutual impact of health status on patients educational and socio-professional life course.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>- Study the factors of heterogeneity of patients' profiles - Explore the causal relation between health status and employment conditions, education, material and economic situation - Assess the patients' needs in care and socio-economic support</measure>
    <time_frame>Once at enrollment</time_frame>
    <description>The perceived impact of disease on education will be confirmed by:&#xD;
Type of education adjustment introduced&#xD;
The level and the cause of leaving full-time education&#xD;
The intensity of school absences&#xD;
The feeling of discrimination on school time&#xD;
The impact of disease on professional life will be measured by:&#xD;
The professional status&#xD;
The sick leaves&#xD;
The feeling of discrimination at work&#xD;
The compatibility of work conditions with the disease&#xD;
The impact of disease on material and economic situation will be assessed by:&#xD;
The income level&#xD;
The patient cost sharing&#xD;
The remaining balance&#xD;
The recognition of handicap&#xD;
The recognition of disability&#xD;
The quality of life score of respondents:&#xD;
- Medical outcome study short form 36 item health survey (MOS SF-36)</description>
  </secondary_outcome>
  <enrollment type="Actual">1088</enrollment>
  <condition>Sickle-cell Disease (SCD)</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adults or parents of minor children with SCD living in France.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Diagnosed with SCD or parent of a minor child diagnosed with SCD&#xD;
&#xD;
          -  Able to speak and understand French&#xD;
&#xD;
          -  Willing to participate to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Person having serious difficulties to read or speak French, unable to answer the&#xD;
             questions&#xD;
&#xD;
          -  Person suffering from other chronic disease which could bias the representation they&#xD;
             have about SCD&#xD;
&#xD;
          -  Patient cured with a bone marrow transplant&#xD;
&#xD;
          -  Patient with mental disorder preventing the patient to understand the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederic Galacteros, MD,PhD,Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Red Cell genetic diseases unity, Henri Mondor Hospital, Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de références syndromes drépanocytaires majeurs thalassémie et autres maladies rares du globule rouge et de l'érythropoïése</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.modalisa-enquete.com/drepatient</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Crosby LE, Joffe NE, Irwin MK, Strong H, Peugh J, Shook L, Kalinyak KA, Mitchell MJ. School Performance and Disease Interference in Adolescents with Sickle Cell Disease. Phys Disabil. 2015;34(1):14-30.</citation>
    <PMID>27547816</PMID>
  </reference>
  <reference>
    <citation>Dos Santos JP, Gomes Neto M. Sociodemographic aspects and quality of life of patients with sickle cell anemia. Rev Bras Hematol Hemoter. 2013;35(4):242-5. doi: 10.5581/1516-8484.20130093.</citation>
    <PMID>24106440</PMID>
  </reference>
  <reference>
    <citation>Gardner K, Douiri A, Drasar E, Allman M, Mwirigi A, Awogbade M, Thein SL. Survival in adults with sickle cell disease in a high-income setting. Blood. 2016 Sep 8;128(10):1436-8. doi: 10.1182/blood-2016-05-716910. Epub 2016 Jul 20.</citation>
    <PMID>27439910</PMID>
  </reference>
  <reference>
    <citation>Habibi A, Arlet JB, Stankovic K, Gellen-Dautremer J, Ribeil JA, Bartolucci P, Lionnet F; centre de référence maladies rares &quot; syndromes drépanocytaires majeurs &quot;. [French guidelines for the management of adult sickle cell disease: 2015 update]. Rev Med Interne. 2015 May 11;36(5 Suppl 1):5S3-84. doi: 10.1016/S0248-8663(15)60002-9. French.</citation>
    <PMID>26007619</PMID>
  </reference>
  <reference>
    <citation>Chapelon E, Garabedian M, Brousse V, Souberbielle JC, Bresson JL, de Montalembert M. Osteopenia and vitamin D deficiency in children with sickle cell disease. Eur J Haematol. 2009 Dec 1;83(6):572-8. doi: 10.1111/j.1600-0609.2009.01333.x. Epub 2009 Aug 13.</citation>
    <PMID>19682065</PMID>
  </reference>
  <reference>
    <citation>Godeau B, Noël V, Habibi A, Schaeffer A, Bachir D, Galactéros F. [Sickle cell disease in adults: which emergency care by the internists?]. Rev Med Interne. 2001 May;22(5):440-51. Review. French.</citation>
    <PMID>11402515</PMID>
  </reference>
  <reference>
    <citation>LINDENBAUM J, KLIPSTEIN FA. FOLIC ACID DEFICIENCY IN SICKLE-CELL ANEMIA. N Engl J Med. 1963 Oct 24;269:875-82.</citation>
    <PMID>14050985</PMID>
  </reference>
  <reference>
    <citation>Noll RB, Vannatta K, Koontz K, Kalinyak K, Bukowski WM, Davies WH. Peer relationships and emotional well-being of youngsters with sickle cell disease. Child Dev. 1996 Apr;67(2):423-36.</citation>
    <PMID>8625722</PMID>
  </reference>
  <reference>
    <citation>Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010 Dec 11;376(9757):2018-31. doi: 10.1016/S0140-6736(10)61029-X. Epub 2010 Dec 3. Review.</citation>
    <PMID>21131035</PMID>
  </reference>
  <reference>
    <citation>Salih KMA. The impact of sickle cell anemia on the quality of life of sicklers at school age. J Family Med Prim Care. 2019 Feb;8(2):468-471. doi: 10.4103/jfmpc.jfmpc_444_18.</citation>
    <PMID>30984656</PMID>
  </reference>
  <reference>
    <citation>Sehlo MG, Kamfar HZ. Depression and quality of life in children with sickle cell disease: the effect of social support. BMC Psychiatry. 2015 Apr 11;15:78. doi: 10.1186/s12888-015-0461-6.</citation>
    <PMID>25880537</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sickle-cell disease</keyword>
  <keyword>quality of life</keyword>
  <keyword>education</keyword>
  <keyword>socio-professional integration</keyword>
  <keyword>france</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

